Discover key highlights in healthcare stocks, including UnitedHealth's surge after a Buffett stake, Eli Lilly lawsuits, Trump pharma tariffs & Bayer's ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

What Happened: Alvarez's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 758 shares of Eli Lilly. The total transaction ...

Texas Attorney General Ken Paxton has filed a lawsuit against U.S. pharmaceutical giant Eli Lilly, alleging the company ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be ...

Huge dividends from Denmark’s weight loss drug industry are result of high-tax and high-investment economy, says Nobel Prize winner Morten Meldal.